OREXO'S RAPINYL NEARING REGULATORY DECISION IN EUROPE

摘要

Orexo's European licensing partner ProStrakan Group plc,for the cancer breakthrough pain product Rapinyl on the European market,has announced that Rapinyl will be referred for review by the Committee for Medicinal Products for Human Use(CHMP)of the EMEA.Of the 25 member states involved in the EU Decentralised Procedure(DCP)for Rapinyl,21 consider this product to be approvable.